Clinical trials · Texas
Ovarian cancer clinical trials in Texas
We’re tracking 132 recruiting ovarian cancer studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Houston, TexasAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Austin, TexasAges 18 years+ - NCT06515613RecruitingPhase 1
Testing CTIM-76 for recurrent ovarian and other advanced cancers
This trial tests a new drug, CTIM-76, in people whose ovarian, testicular, or endometrial cancer has come back and is not responding to standard treatments. It aims to see if the drug can shrink tumors or stop them from growing.
Dallas, TexasAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Fort Worth, TexasAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Houston, TexasAges 18 years+ - NCT07424547RecruitingPhase 1
Study of SYS6043 for advanced or metastatic solid tumors
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
Austin, TexasAges 18 years+ - NCT00539162Recruiting
CA-125 and other tests to check for early ovarian cancer risk
This study looks at how well a blood test called CA-125, along with other markers and checkups, can detect ovarian cancer early. It’s for women considered low risk who will do regular blood tests and possibly a vaginal ultrasound if results suggest it.
Austin, TexasAges 50–74 - NCT07216105RecruitingPhase 1
New immune cell treatment for advanced solid tumors
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
San Antonio, TexasAges 18 years+ - NCT06036810Recruiting
Spanish decision tool for ovarian cancer maintenance
This study tests a Spanish-language decision tool to help people with advanced ovarian cancer choose the best maintenance therapy after chemotherapy. It is for patients who can read or speak Spanish and are eligible for maintenance treatment.
Houston, TexasAges 18 years+ - NCT05123807RecruitingPhase 2
Surgery plus heated chemotherapy for recurrent mucinous ovarian cancer
This trial studies a planned surgery to remove as much cancer as possible, followed by heated chemotherapy placed in the belly (called HIPEC). It’s for people with recurrent mucinous ovarian cancer, aiming to control the cancer and improve outcomes.
Houston, TexasAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Amarillo, TexasAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Austin, TexasAges 18 years+ - NCT06843447RecruitingPhase 1/Phase 2
Study of raludotatug deruxtecan for ovarian cancer
This study tests a new drug called raludotatug deruxtecan for people with certain types of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The drug is designed to target and kill cancer cells while sparing healthy tissue. It may be used alone or with other treatments, depending on the study group.
Fort Worth, TexasAges 18 years+ - NCT06072781RecruitingPhase 3
Study of Avutometinib + Defactinib for recurrent low-grade ovarian cancer
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
Austin, TexasAges 18 years+ - NCT05568680RecruitingPhase 1
Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Houston, TexasAges 18 years+ - NCT07524322RecruitingPhase 1
RGT-490 for Advanced Cancers With PIK3CA Mutations
This study tests a new drug called RGT-490 in patients with advanced solid tumors (cancers that have spread or cannot be removed by surgery) that have a specific genetic change called a PIK3CA mutation. The drug is designed to block a protein involved in cancer cell growth.
Houston, TexasAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
Dallas, TexasAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Austin, TexasAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Dallas, TexasAges 18 years+ - NCT06840886RecruitingPhase 1
Study of PHST001 for advanced solid tumors
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
Fort Worth, TexasAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Abilene, TexasAges 18 years+ - NCT07023627RecruitingPhase 2
New pill for platinum-resistant ovarian cancer with cyclin E1
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
Austin, TexasAges 18–99 - NCT07109726RecruitingPhase 1/Phase 2
Testing TER-2013 for advanced tumors with AKT/PI3K/PTEN changes
This trial tests a new drug called TER-2013, alone or combined with another drug (fulvestrant), for people with advanced solid tumors that have specific genetic changes in the AKT/PI3K/PTEN pathway. It aims to see if the drug is safe and effective.
Austin, TexasAges 18 years+
Ovarian cancer trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting ovarian cancer studies listed above.
- The University of Texas MD Anderson Cancer Center · 13 studies
- Houston Methodist Hospital · 3 studies
- Texas Oncology - DFW · 3 studies
- NEXT Oncology · 2 studies
- START Center for Clinical Research · 2 studies
- START San Antonio · 2 studies
- Avenzo Therapeutics Recruiting Site
- Baylor University Medical Center
What taking part in a ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Ovarian cancer trials in other states
Common questions
- Are there ovarian cancer clinical trials in Texas?
- Yes. We're currently tracking 132 recruiting ovarian cancer studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ovarian cancer study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ovarian cancer studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.